Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Calliditas Therapeutics AB (NASDAQ:CALT) received full FDA approval for Tarpeyo, its treatment for IgAN, marking it as the first fully approved treatment for this condition based on kidney function. Tarpeyo, priced at $15,123 per month, is exclusively distributed through McKesson Corporation's (NYSE:MCK) specialty pharmacy, Biologics. Competitors like Travere Therapeutics Inc (NASDAQ:TVTX), Roche Holdings AG (OTC:RHHBY), Novartis AG (NYSE:NVS), and Vera Therapeutics Inc (NASDAQ:VERA) are developing treatments for IgAN. CALT shares rose 14.40% in premarket trading.

Portfolio Pulse from Vandana Singh

December 21, 2023 | 1:54 pm

Roche's navify digital solutions, including navify Tumor Board, navify POC Operations, and navify Lab Operations, have received excellent ratings from healthcare professionals according to KLAS Research. The solutions are praised for improving tumor board meetings, enhancing point-of-care device management, and automating lab processes, with 100% of professionals indicating they would repurchase.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 7:06 am

Fractyl Health, a company developing therapies for type 2 diabetes and obesity, has filed for a $100M IPO. Its lead product, Revita DMR System, is approved in Europe and is undergoing a pivotal study with results expected in 4Q24. Fractyl is also working on Rejuva, a gene therapy platform, with plans to nominate its first candidate in 1Q24. The company will list on Nasdaq under the symbol GUTS. This follows Roche's acquisition of Carmot Therapeutics and promising data from Fractyl's Rejuva compared to Novo Nordisk's semaglutide.

Portfolio Pulse from Vandana Singh

December 15, 2023 | 7:39 pm

Poseida Therapeutics Inc (PSTX) reported positive early results from a Phase 1 study of P-BCMA-ALLO1, a CAR-T therapy candidate for multiple myeloma, in partnership with Roche Holdings AG (RHHBY). The study showed an 82% overall response rate, with high rates of partial and complete responses and well-tolerated safety profile. The news has led to a 20.6% increase in PSTX shares in premarket trading.

Portfolio Pulse from Vandana Singh

December 11, 2023 | 4:17 pm

Roche's Genentech presented new data at the 65th ASH Annual Meeting showing durable responses from its fixed-duration Columvi and Lunsumio in treating heavily pre-treated lymphomas. The data also support the potential of combination regimens in earlier treatment settings, reinforcing ongoing Phase III studies.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 7:08 am

Johnson & Johnson's CEO Joaquin Duato stated that the company is not planning to enter the weight-loss drug market due to existing competition, focusing instead on expanding in neurology and oncology. Eli Lilly, Novo Nordisk, and Roche Holdings are already significant players in the obesity treatment market. Roche recently acquired Carmot Therapeutics for $2.7 billion. Altimmune's stock rose after Phase 2 obesity trial results, while Pfizer's fell due to high discontinuation rates in a trial. JNJ shares dropped 1.11% recently.

Portfolio Pulse from Vandana Singh

December 06, 2023 | 4:23 pm

Genentech, a member of the Roche Group, announced positive Phase III study results for Inavolisib in treating advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Portfolio Pulse from Benzinga Newsdesk

December 05, 2023 | 6:07 am

Jim Cramer highlighted the 'transformational' impact of GLP-1 weight loss drugs like Ozempic, suggesting investors focus on potential winners from the growing demand for these drugs. Eli Lilly (LLY) and Novo Nordisk (NVO), manufacturers of GLP-1 drugs, are immediate beneficiaries. Other sectors like high-protein food manufacturers and construction companies for pharmaceutical facilities, as well as the apparel sector, could also benefit. Roche Holding AG (RHHBY) has entered the competition by acquiring Carmot Therapeutics, indicating a heated market for obesity treatment drugs.

Portfolio Pulse from Benzinga Neuro

December 05, 2023 | 1:24 am

Roche Holding AG (OTC:RHHBY) is set to acquire Carmot Therapeutics to enter the competitive weight loss drug market, challenging Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY). Carmot's portfolio includes several incretin-based treatments for obesity and type 2 diabetes, with the lead asset CT-388 ready for Phase-2 trials. Roche will pay $2.7 billion in cash plus up to $400 million in milestone payments. The acquisition will also give Roche access to Carmot's discovery platform, enhancing its R&D in metabolism-related diseases. The deal is expected to close in Q1 2024.

Portfolio Pulse from Vandana Singh

December 04, 2023 | 12:04 pm

AstraZeneca plc (NASDAQ:AZN) has entered into a partnership with Absci Corporation (NASDAQ:ABSI) to develop an AI-driven antibody for cancer treatment, with a deal value of up to $247 million. Absci will receive an upfront fee, R&D funding, milestone payments, and royalties on product sales. The collaboration aims to leverage Absci's AI technology for protein analysis to accelerate drug discovery. This move is part of a broader trend of incorporating AI into pharmaceutical research, as seen with Genentech's recent partnership with NVIDIA Corporation (NASDAQ:NVDA). ABSI stock rose 8.62% in premarket trading.

Portfolio Pulse from Vandana Singh

December 04, 2023 | 11:58 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.